News
CSTL
31.43
-2.51%
-0.81
Weekly Report: what happened at CSTL last week (0803-0807)?
Weekly Report · 3d ago
Castle Biosciences Ups 2026 Outlook Amid Growth
TipRanks · 3d ago
Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript
NASDAQ · 5d ago
Castle Biosciences price target raised to $44 from $40 at BTIG
TipRanks · 08/04 11:06
Castle Biosciences Reaffirmed at Buy as Strong Q2 and Raised 2026 Outlook Support 43% Upside to Unchanged $40 Price Target
TipRanks · 08/03 11:45
Castle Biosciences Price Target Raised to $44.00/Share From $40.00 by BTIG
Dow Jones · 08/03 10:45
Castle Biosciences Is Maintained at Buy by BTIG
Dow Jones · 08/03 10:45
BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44
Benzinga · 08/03 10:35
Weekly Report: what happened at CSTL last week (0727-0731)?
Weekly Report · 08/03 09:46
Castle Biosciences price target raised to $57 from $52 at Lake Street
TipRanks · 07/31 12:56
Castle Biosciences price target lowered to $36 from $43 at Baird
TipRanks · 07/31 11:21
Castle Biosciences Q2 Earnings Call Highlights
NASDAQ · 07/30 22:04
Castle Biosciences Lifts 2026 Outlook After Q2 Growth
TipRanks · 07/30 21:10
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 07/30 21:05
Castle Biosciences reports Q2 EPS (7c), consensus (41c)
TipRanks · 07/30 20:17
Castle Biosciences raises 2026 revenue view to $365M-$375M from $345M-$355M
TipRanks · 07/30 20:16
*Castle Biosciences 2Q Rev $103.5M >CSTL
Dow Jones · 07/30 20:05
*Castle Biosciences 2Q Loss $2.06M >CSTL
Dow Jones · 07/30 20:05
Press Release: Castle Biosciences Reports Second -2-
Dow Jones · 07/30 20:05
*Castle Biosciences 2Q Loss/Shr 7c >CSTL
Dow Jones · 07/30 20:05
More
Webull provides a variety of real-time CSTL stock news. You can receive the latest news about Castle Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About CSTL
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).